<DOC>
	<DOCNO>NCT00082862</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin gemcitabine , work different way stop tumor cell divide stop grow die . Giving low-dose interferon alfa metronomic ( regularly time ) schedule may stop growth cancer stop blood flow tumor . Fever-range ( 101° F ) whole-body hyperthermia kill tumor cell heat several degree normal body temperature . Combining cisplatin , gemcitabine , low-dose interferon alfa fever-range whole-body hyperthermia may kill tumor cell . PURPOSE : This phase II trial study well give cisplatin , gemcitabine , metronomic low-dose interferon alfa together fever-range whole-body hyperthermia work treat patient inoperable metastatic pancreatic cancer .</brief_summary>
	<brief_title>Cisplatin , Metronomic Low-Dose Interferon Alfa , Gemcitabine , Fever-Range Whole-Body Hyperthermia Treating Patients With Inoperable Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine tumor response patient inoperable metastatic pancreatic cancer treat cisplatin , metronomic low-dose interferon alfa , gemcitabine , fever-range whole-body hyperthermia . - Determine toxicity regimen patient . - Determine survival patient treat regimen . - Determine change quality life patient treat regimen . Secondary - Determine whether inoperable tumor convert operable patient treat regimen . - Determine change cellular cytokine immune function patient treat regimen . OUTLINE : Patients stratify accord disease stage ( metastatic v inoperable ) . Patients receive cisplatin IV 4-6 hour day 1 , interferon alfa subcutaneously daily day 1-28 , gemcitabine IV 1 hour day 3 10 . Patients undergo fever-range whole-body hyperthermia ( 40°C 6 hour ) day 3 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Quality life assess baseline treatment course . PROJECTED ACCRUAL : A total 18-48 patient ( 9-24 per stratum ) accrue study within 4 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm pancreatic carcinoma Inoperable metastatic disease Measurable lesion physical examination , CT scan , MRI Carcinomatous hepatomegaly consider measurable palpable liver edge clearly extend &gt; 15 cm costal margin xiphoid process No known brain metastasis CT scan MRI PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy At least 12 week Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin &gt; 10.0 g/dL Platelet count ≥ 90,000/mm^3 Bone marrow cellularity normal bone marrow biopsy No serious coagulopathy disorder Hepatic Bilirubin ≤ 2.5 mg/dL SGPT SGOT ≤ 2 time upper limit normal PT &lt; 14 second PTT &lt; 35 second INR &lt; 1.5 Renal Creatinine ≤ 1.8 mg/dL Creatinine clearance ≥ 45 mL/min Blood urea nitrogen ≤ 25 mg/dL Cardiovascular Adequate cardiovascular function document follow : History physical examination Stress exercise test ( MUGA echocardiogram ) rest blood pressure , heart rate , LVEF increase appropriately exercise LVEF ≥ 45 % No myocardial infarction within past 6 month No symptomatic coronary artery disease No angina No unstable blood pressure No congestive heart failure No significant arrhythmia No conduction disturbance No thromboembolic disease No uncontrolled hypertension Pulmonary Complete pulmonary function study follow arterial blood gas value : FEV_1 ≥ 70 % predict Arterial PO_2 ≥ 60 mm Hg room air PCO_2 appropriate pH appropriate No massive ( ≥ 30 % ) lung disease DLCO &gt; 50 % predict Other No prior concurrent seizure CNS disorder No prior malignant hyperthermia general anesthesia No insulindependent diabetes mellitus No significant emotional instability No medical problem would preclude treatment wholebody hyperthermia HIV negative Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy Prior biologic therapy allow Chemotherapy No prior cisplatin gemcitabine Endocrine therapy No concurrent adrenal corticosteroid Radiotherapy More 3 week since prior radiotherapy Surgery More 6 day since prior major thoracic abdominal surgery Prior surgical resection tumor subsequent recurrence allow Other No concurrent cardiac glycosides No concurrent antiangina arrhythmia drug No concurrent thrombolytic agent No concurrent anticoagulants No concurrent aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>